GlaxoSmithKline (GSK) Price & Analysis

Compare

1,064 Followers

GSK Stock Chart & Stats

Day’s Range― - ―

52-Week Range1,242.50p - 1,684.50p

Previous CloseN/A

Volume367.08K

Average Volume (3M)7.50M

Market Cap

£67.28B

Enterprise Value73.93B

Total Cash (Recent Filing)£3.62B

Total Debt (Recent Filing)£17.35B

Price to Earnings (P/E)19.9

Beta0.81

Next Earnings

Oct 29, 2025

EPS Estimate

0.47

Last Dividend Ex-Date

Aug 14, 2025

Dividend Yield3.56%

Share Statistics

EPS (TTM)0.45

Shares Outstanding4,067,375,500

10 Day Avg. Volume9,058,555

30 Day Avg. Volume7,497,709

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)4.02

Price to Sales (P/S)1.75

P/FCF Ratio15.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,587.23

Price Target Upside-3.63% Downside

Rating ConsensusHold

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Leadership ChangeNew CEO appointment is likely to shift sentiment positively relative to our Underperform thesis.

Strategic FocusChange to Miels is likely to be viewed positively given Miels has a strong Pharma focus at a time where business is shifting to specialty drivers.

Bears Say

Earnings ImpactHigher R&D spending is anticipated to negatively impact future earnings per share.

Product Pipeline UncertaintyUncertainty exists about whether future product launches, such as depemokimab, can compensate for current challenges and competitive pressures.

Regulatory ChallengesConcerns exist over the delayed approval process for Blenrep, a key launch for GSK, due to negative advisory committee feedback and the submission of additional data.

GlaxoSmithKline News

Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role

Welcome to the latest edition of “Sector Spotlight,” where The Fly looks at a new industry every week...

6h ago

Trump Weekly: White House announces drug pricing deal with Pfizer

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

7h ago

Trump Trade: White House announces drug pricing deal with Pfizer

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2d ago

AZN

Trump outlines plan for next round of Medicare drug price talks, Bloomberg says

The Trump administration issued a final plan for how it will carry out the third round of the...

2d ago

AZN

BMY

White House announces deal with Pfizer for ‘most-favored-nation pricing’

President Donald Trump announced the “first agreement with a major pharmaceutical company,” Pfizer (PFE), to bring American drug...

3d ago

AZN

BMY

Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices

Publicly traded drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ),...

3d ago

AZN

BMY

EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz

The major averages were mixed near noon as the Street attempts to regain its footing after stocks ended...

4d ago

GSK appoints Luke Miels as CEO Designate

GSK (GSK) announces that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO...

5d ago

GSK

Trump Weekly: President threatens new tariffs, announces TikTok deal

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

7d ago

Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz

The major averages were mixed near noon, with the Dow and S&P 500 edging higher following recent declines...

7d ago

GSK Enhances Shareholder Value with Strategic Buyback

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK plc announced the purchase of 335,000 of...

19h ago

Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Uncertain Future Performance and Competitive Pressures

Analyst Sachin Jain from Bank of America Securities maintained a Sell rating on GlaxoSmithKline and keeping the price...

2d ago

GSK

GSK Announces Total Voting Rights and Capital Update

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK plc has announced its total voting rights...

2d ago

GSK Enhances Shareholder Value with Strategic Buyback

GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK has announced the purchase of 305,000 ordinary shares as...

3d ago

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest share price was 1242.50p and its highest was 1684.50p in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is £67.28B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 25 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Quarterly dividend of 16p which represents an annual dividend yield of 3.56%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 0.47.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 4,067,375,500 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.597%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GB:GSK

GlaxoSmithKline Stock Smart Score

Outperform

Fundamentals

Return on Equity

23.47%

Trailing 12-Months

Asset Growth

2.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company headquartered in Brentford, United Kingdom. It operates in three main sectors: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK develops and manufactures a wide range of products, including innovative medicines for respiratory, HIV, and oncology conditions, vaccines for diseases such as influenza and shingles, and consumer healthcare products like oral health, pain relief, and wellness solutions.

GlaxoSmithKline (GSK) Earnings & Revenues

Historic Earnings Reports

GSK Stock 12 Month Forecast

Average Price Target

1,587.23p

▼(-3.63% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1289":"1,289p","1730":"1,730p","2171":"2,171p","1509.5":"1,509.5p","1950.5":"1,950.5p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1587.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.59K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.29K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1289,1509.5,1730,1950.5,2171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1447.5,1503.076923076923,1558.6538461538462,1614.2307692307693,1669.8076923076924,1725.3846153846155,1780.9615384615386,1836.5384615384614,1892.1153846153848,1947.6923076923076,2003.269230769231,2058.846153846154,2114.423076923077,{"y":2170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1447.5,1458.2484615384615,1468.9969230769232,1479.7453846153846,1490.493846153846,1501.2423076923078,1511.9907692307693,1522.7392307692307,1533.4876923076922,1544.236153846154,1554.9846153846154,1565.7330769230769,1576.4815384615385,{"y":1587.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1447.5,1435.3846153846155,1423.2692307692307,1411.1538461538462,1399.0384615384614,1386.923076923077,1374.8076923076924,1362.6923076923076,1350.576923076923,1338.4615384615386,1326.3461538461538,1314.2307692307693,1302.1153846153845,{"y":1290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1577.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1454.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1356.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1296.34,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1301.18,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1357.71,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1433.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1435.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1429.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1396.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1380.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1447.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >